The role of IFN-γ in tumor transplantation immunity and inhibition of chemical carcinogenesis

Current Opinion in Immunology

Volumn 15, Issue 2, 2003, Pages 148-154

  Blankenstein, Thomas ^a,b   Qin, Zhihai ^b  

^a MAX DELBRÜCK CENTER FOR MOLECULAR MEDICINE   (Germany)

^b FREIE UNIVERSITÄT BERLIN   (Germany)

Author keywords

[No Author keywords available]

Indexed keywords

3 METHYLCHOLANTHRENE; CARCINOGEN; CD4 ANTIGEN; CD8 ANTIGEN; GAMMA INTERFERON; GAMMA INTERFERON RECEPTOR; INTERLEUKIN 10; INTERLEUKIN 12; MAJOR HISTOCOMPATIBILITY ANTIGEN CLASS 1; MAJOR HISTOCOMPATIBILITY ANTIGEN CLASS 2; TUMOR NECROSIS FACTOR;

BLOOD VESSEL; CANCER INHIBITION; CANCER TRANSPLANTATION; CARCINOGENESIS; CELL PROTECTION; DIFFUSION; DNA DAMAGE; ENCAPSULATION; HISTOCOMPATIBILITY; HOST CELL; IMMUNITY; NONHUMAN; PROTEIN EXPRESSION; REGULATORY MECHANISM; REVIEW; TISSUE INJURY; TUMOR BLOOD FLOW; TUMOR CELL; TUMOR REJECTION;

EID: 0037375553     PISSN: 09527915     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0952-7915(03)00007-4     Document Type: Review

References (56)

1. Farrar M.A., Schreiber R.D. The molecular cell biology of interferon-gamma and its receptor. Annu. Rev. Immunol. 11:1993;571-611.
2. Boehm U., Klamp T., Groot M., Howard J.C. Cellular responses to interferon-gamma. Annu. Rev. Immunol. 15:1997;749-795.
3. Harris D.P., Haynes L., Sayles P.C., Duso D.K., Eaton S.M., Lepak N.M., Johnson L.L., Swain S.L., Lund F.E. Reciprocal regulation of polarized cytokine production by effector B and T cells. Nat. Immunol. 1:2000;475-482.
4. Munder M., Mallo M., Eichmann K., Modolell M. Murine macrophages secrete interferon gamma upon combined stimulation with interleukin (IL)-12 and IL-18: a novel pathway of autocrine macrophage activation. J. Exp. Med. 187:1998;2103-2108.
5. Ibe S., Qin Z., Schuler T., Preiss S., Blankenstein T. Tumor rejection by disturbing tumor stroma cell interactions. J. Exp. Med. 194:2001;1549-1559 This study shows that Cy induces tumor rejection by acting on the tumor stroma. Within hours after treatment, T cells in the tumor are inactivated, macrophages stop producing IL-10 and start to produce IFN-γ, and the tumor vasculature is destroyed in an IFN-γR dependent fashion.
6. Rottenberg M.E., Gigliotti-Rothfuchs A., Wigzell H. The role of IFN-γ in the outcome of chlamydial infection. Curr. Opin. Immunol. 14:2002;444-451.
7. Goes N., Sims T., Urmson J., Vincent D., Ramassar V., Halloran P.F. Disturbed MHC regulation in the IFN-γ knockout mouse. Evidence for three states of MHC expression with distinct roles for IFN-γ J. Immunol. 155:1995;4559-4566.
8. Gansbacher B., Bannerji R., Daniels B., Zier K., Cronin K., Gilboa E. Retroviral vector-mediated gamma-interferon gene transfer into tumor cells generates potent and long lasting antitumor immunity. Cancer Res. 50:1990;7820-7825.
9. Hock H., Dorsch M., Kunzendorf U., Qin Z., Diamantstein T., Blankenstein T. Mechanisms of rejection induced by tumor cell-targeted gene transfer of interleukin 2, interleukin 4, interleukin 7, tumor necrosis factor, or interferon gamma. Proc. Natl. Acad. Sci. U.S.A. 90:1993;2774-2778.
10. Dighe A.S., Richards E., Old L.J., Schreiber R.D. Enhanced in vivo growth and resistance to rejection of tumor cells expressing dominant negative IFN-γ receptors. Immunity. 1:1994;447-456.
11. Hung K., Hayashi R., Lafond-Walker A., Lowenstein C., Pardoll D., Levitsky H. The central role of CD4(+) T cells in the antitumor immune response. J. Exp. Med. 188:1998;2357-2368.
12. Prevost-Blondel A., Neuenhahn M., Rawiel M., Pircher H. Differential requirement of perforin and IFN-gamma in CD8 T cell-mediated immune responses against B16.F10 melanoma cells expressing a viral antigen. Eur. J. Immunol. 30:2000;2507-2515.
13. + T cell-mediated tumor rejection involves inhibition of angiogenesis that is dependent on IFN- gamma receptor expression by nonhematopoietic cells. Immunity. 12:2000;677-686.
14. + tumor-infiltrating lymphocytes. J. Exp. Med. 173:1991;647-658.
15. + T cells are not excluded. Enrichment of tumor-reactive T cells is also shown for human renal cell carcinoma.
16. Nanni P., Nicoletti G., De Giovanni C., Landuzzi L., Di Carlo E., Cavallo F., Pupa S.M., Rossi I., Colombo M.P., Ricci C.et al. Combined allogeneic tumor cell vaccination and systemic interleukin 12 prevents mammary carcinogenesis in HER-2/neu transgenic mice. J. Exp. Med. 194:2001;1195-1205 Cancer-prone HER-2/neu transgenic mice can be successfully immunized with antigen-positive allogeneic tumor cells and IL-12. As shown by backcrosses with knockout mice, vaccination efficacy is abrogated in the absence of IFN-γ.
17. Peng L., Krauss J.C., Plautz G.E., Mukai S., Shu S., Cohen P.A. T cell-mediated tumor rejection displays diverse dependence upon perforin and IFN-γ mechanisms that cannot be predicted from in vitro T cell characteristics. J. Immunol. 165:2000;7116-7124.
18. Winter H., Hu H.M., McClain K., Urba W.J., Fox B.A. Immunotherapy of melanoma: a dichotomy in the requirement for IFN-γ in vaccine-induced antitumor immunity versus adoptive immunotherapy. J. Immunol. 166:2001;7370-7380.
19. Hock H., Dorsch M., Kunzendorf U., Uberla K., Qin Z., Diamantstein T., Blankenstein T. Vaccinations with tumor cells genetically engineered to produce different cytokines: effectivity not superior to a classical adjuvant. Cancer Res. 53:1993;714-716.
20. Dranoff G., Jaffee E., Lazenby A., Golumbek P., Levitsky H., Brose K., Jackson V., Hamada H., Pardoll D., Mulligan R.C. Vaccination with irradiated tumor cells engineered to secrete murine granulocyte-macrophage colony-stimulating factor stimulates potent, specific, and long-lasting anti-tumor immunity. Proc. Natl. Acad. Sci. U.S.A. 90:1993;3539-3543.
21. Qin Z., Harders C., Cao X., Huber C., Blankenstein T., Seliger B. Increased tumorigenicity, but unchanged immunogenicity, of transporter for antigen presentation 1-deficient tumors. Cancer Res. 62:2002;2856-2860.
22. Qin Z., Noffz G., Mohaupt M., Blankenstein T. Interleukin-10 prevents dendritic cell accumulation and vaccination with granulocyte-macrophage colony-stimulating factor gene-modified tumor cells. J. Immunol. 159:1997;770-776.
23. -) was less effective compared to subcutaneous immunization. B cells were not responsible for decreased generation of tumor immunity following intrasplenic immunization.
24. Heath W.R., Carbone F.R. Cross-presentation, dendritic cells, tolerance and immunity. Annu. Rev. Immunol. 19:2001;47-64.
25. + T cells. IL-4 probably acts on antigen-presenting cells.
26. Schuler T., Blankenstein T. Naïve CD8(+) but not CD4(+) T cells induce maturation of dendritic cells. J. Mol. Med. 80:2002;533-541.
27. Nguyen L.T., Elford A.R., Murakami K., Garza K.M., Schoenberger S.P., Odermatt B., Speiser D.E., Ohashi P.S. Tumor growth enhances cross-presentation leading to limited T cell activation without tolerance. J. Exp. Med. 195:2002;423-435 This study employs the RIP-TAG pancreatic tumor model, in which the LCMV-gp33 surrogate antigen is expressed by tumor cells. The mice express the SV40 large T antigen under the control of the insulin promoter. CTL activation by cross-priming spontaneously occurred in mice with tumor burden, thus suggesting that cross-priming depends on high amounts of antigen. The CTL were not tolerized.
28. Cayeux S., Richter G., Noffz G., Dorken B., Blankenstein T. Influence of gene-modified (IL-7, IL-4, and B7) tumor cell vaccines on tumor antigen presentation. J. Immunol. 158:1997;2834-2841.
29. Cayeux S., Richter G., Becker C., Pezzutto A., Dorken B., Blankenstein T. Direct and indirect T cell priming by dendritic cell vaccines. Eur. J. Immunol. 29:1999;225-234.
30. Zinkernagel R.M. On cross-priming of MHC class I-specific CTL: rule or exception? Eur. J. Immunol. 32:2002;2385-2392 In opposition to our view that CTL raised against tumor-derived antigens are usually induced by antigen cross-presentation, it is argued in this review that direct priming by tumor cells (e.g. after migration to secondary lymphoid organs) is the common mechanism of CTL activation.
31. Coughlin C.M., Salhany K.E., Gee M.S., LaTemple D.C., Kotenko S., Ma X., Gri G., Wysocka M., Kim J.E., Liu L.et al. Tumor cell responses to IFN-gamma affect tumorigenicity and response to IL-12 therapy and antiangiogenesis. Immunity. 9:1998;25-34.
32. Mumberg D., Monach P.A., Wanderling S., Philip M., Toledano A.Y., Schreiber R.D., Schreiber H. CD4(+) T cells eliminate MHC class II-negative cancer cells in vivo by indirect effects of IFN-γ Proc. Natl. Acad. Sci. U.S.A. 96:1999;8633-8638.
33. Pulaski B.A., Smyth M.J., Ostrand-Rosenberg S. Interferon-gamma-dependent phagocytic cells are a critical component of innate immunity against metastatic mammary carcinoma. Cancer Res. 62:2002;4406-4412.
34. Segal J.G., Lee N.C., Tsung Y.L., Norton J.A., Tsung K. The role of IFN-γ in rejection of established tumors by IL-12: source of production and target. Cancer Res. 62:2002;4696-4703.
35. Winter H., Hu H.M., Urba W.J., Fox B.A. Tumor regression after adoptive transfer of effector T cells is independent of perforin or Fas ligand (APO-1L/CD95L). J. Immunol. 163:1999;4462-4472.
36. Folkman J. Tumor angiogenesis: therapeutic implications. N. Engl. J. Med. 285:1971;1182-1186.
37. Dvorak H.F. Tumors: wounds that do not heal. Similarities between tumor stroma generation and wound healing. N. Engl. J. Med. 315:1986;1650-1659.
38. Singh S., Ross S.R., Acena M., Rowley D.A., Schreiber H. Stroma is critical for preventing or permitting immunological destruction of antigenic cancer cells. J. Exp. Med. 175:1992;139-146.
39. Coussens L.M., Tinkle C.L., Hanahan D., Werb Z. MMP-9 supplied by bone marrow-derived cells contributes to skin carcinogenesis. Cell. 103:2000;481-490.
40. Lin E.Y., Nguyen A.V., Russell R.G., Pollard J.W. Colony-stimulating factor 1 promotes progression of mammary tumors to malignancy. J. Exp. Med. 193:2001;727-740 In this publication it is shown that in oncogene-transgenic mice malignant mammary carcinomas develop. If, in addition, the mice have a macrophage (CSF-1) defect, tumors develop normally but cannot progress to malignancy. This illustrates the important role of inflammation and tumor stroma for tumor progression.
41. Sica A., Saccani A., Bottazzi B., Polentarutti N., Vecchi A., van Damme J., Mantovani A. Autocrine production of IL-10 mediates defective IL-12 production and NF-κB activation in tumor-associated macrophages. J. Immunol. 164:2000;762-767.
42. Ganss R., Ryschich E., Klar E., Arnold B., Hammerling G.J. Combination of T-cell therapy and trigger of inflammation induces remodeling of the vasculature and tumor eradication. Cancer Res. 62:2002;1462-1470 The authors show that adoptive T-cell therapy of mice with primary tumors is effective only when the host is irradiated before T-cell transfer. They argue that irradiation causes inflammation, which allows T cells to be effective. During tumor rejection, the vasculature reverts to a normal phenotype. The involvement of IFN-γ and other anti-angiogenic factors are suggested.
43. Dudley M.E., Wunderlich J.R., Robbins P.F., Yang J.C., Hwu P., Schwartzentruber D.J., Topalian S.L., Sherry R., Restifo N.P., Hubicki A.M.et al. Cancer regression and autoimmunity in patients after clonal repopulation with antitumor lymphocytes. Science. 298:2002;850-854 In an earlier publication, Greenberg et al. [56] showed that in mice adoptive T-cell therapy is effective only if the tumor-bearing mice are pretreated with Cy. In this study, this approach is employed in the clinic. Adoptively transferred T cells expand and cause tumor regression in some melanoma patients if they are pretreated by Cy and fludarabine. The authors suggest that the chemotherapy either allows homeostatic T-cell expansion or, alternatively, eliminates suppressor T cells.
44. Ostler T., Davidson W., Ehl S. Virus clearance and immunopathology by CD8(+) T cells during infection with respiratory syncytial virus are mediated by IFN-γ Eur. J. Immunol. 32:2002;2117-2123 This study demonstrates that virus clearance and immunopathology require IFN-γ but not perforin, Fas-ligand or TNF.
45. Nansen A., Jensen T., Christensen J.P., Andreasen S.O., Ropke C., Marker O., Thomsen A.R. Compromised virus control and augmented perforin-mediated immunopathology in IFN-γ-deficient mice infected with lymphocytic choriomeningitis virus. J. Immunol. 163:1999;6114-6122.
46. Qin Z., Kim H.J., Hemme J., Blankenstein T. Inhibition of methylcholanthrene-induced carcinogenesis by an interferon gamma receptor-dependent foreign body reaction. J. Exp. Med. 195:2002;1479-1490 This study shows that MCA-induced but not p53 deficiency-induced tumor development is increased in IFN-γR KO mice. Encapsulation of the carcinogen in the course of a tissue repair response is suggested as a protective mechanism against the chemical carcinogen. This mechanism is different from T-cell mediated immunosurveillance.
47. Kaplan D.H., Shankaran V., Dighe A.S., Stockert E., Aguet M., Old L.J., Schreiber R.D. Demonstration of an interferon γ-dependent tumor surveillance system in immunocompetent mice. Proc. Natl. Acad. Sci. U.S.A. 95:1998;7556-7561.
48. Johnsen A.K., France J., Nagy N., Askew D., Abdul-Karim F.W., Gerson S.L., Sy M.S., Harding C.V. Systemic deficits in transporter for antigen presentation (TAP)-1 or proteasome subunit LMP2 have little or no effect on tumor incidence. Int. J. Cancer. 91:2001;366-372.
49. Willimsky G., Blankenstein T. Interleukin-7/B7.1-encoding adenoviruses induce rejection of transplanted but not nontransplanted tumors. Cancer Res. 60:2000;685-692.
50. Burnet F.M. The concept of immunological surveillance. Progr. Exp. Tumor Res. 13:1970;1-27.
51. Taniguchi T., Ogasawara K., Takaoka A., Tanaka N. IRF family of transcription factors as regulators of host defense. Annu. Rev. Immunol. 19:2001;623-655.
52. Shankaran V., Ikeda H., Bruce A.T., White J.M., Swanson P.E., Old L.J., Schreiber R.D. IFN-γ and lymphocytes prevent primary tumour development and shape tumour immunogenicity. Nature. 410:2001;1107-1111.
53. Stutman O. Tumor development after 3-methylcholanthrene in immunologically deficient athymic-nude mice. Science. 183:1974;534-536.
54. Engel A.M., Svane I.M., Rygaard J., Werdelin O. MCA sarcomas induced in scid mice are more immunogenic than MCA sarcomas induced in congenic, immunocompetent mice. Scand. J. Immunol. 45:1997;463-470.
55. Schüler T., Qin Z., Ibe S., Noben-Trauth N., Blankenstein T. Th1 associated and cytotoxic T lymphocyte mediated tumor immunity is impaired in IL-4 deficient mice. J. Exp. Med. 189:1999;803-810.
56. Greenberg P., Kern D., Cheever M. Therapy of disseminated murine leukaemia with cyclophosphamide and immune Ly-1+, 2- T cells. J. Exp. Med. 161:1985;1122-1134.